How CAR-T cell Therapy Works: Step-by-Step Guide

For many cancerpatients like Hendrik who have recently recovered from cancer through MediGence at Fortis, CAR-T cell therapy represents a beacon of hope when other treatments have failed. This innovative approach harnesses the power of the bodyâ€™s own immune system to attack cancer cells. But how exactly does CAR-T therapy work? Here's a detailed, step-by-step guide to help patients and their families understand the process.

Step 1: Collecting T Cells

The process begins with a procedure called leukapheresis, where a patient's T cells (a type of white blood cell crucial for immune defence) are extracted from the bloodstream. Blood is drawn through an IV, and a machine separates the T cells before returning the rest of the blood to the body. This step can take a few hours and may require multiple sessions.

Step 2: Genetic Modification in the Lab

Once collected, the T cells are sent to a specialized laboratory where they are genetically engineered to express chimeric antigen receptors (CARs). These receptors act like homing beacons that help T cells recognize and attack specific cancer cells.

Step 3: Expanding the CAR-T Cells

After modification, the newly engineered CAR-T cells are grown in large numbers to ensure they are strong enough to fight the cancer. This process, called ex vivo expansion, takes about two to four weeks.

Step 4: Pre-Treatment Conditioning (Lymphodepletion)

Before receiving the CAR-T cells, patients undergo a short course of low-dose chemotherapy. This step, known as lymphodepletion, prepares the body by reducing existing immune cells, making space for the new CAR-T cells to work effectively.

Step 5: Infusion of CAR-T Cells

Once the modified T cells are ready, they are infused back into the patientâ€™s bloodstream through an IV drip. This infusion usually takes a few minutes to an hour and is done in a hospital setting under close medical supervision.

Step 6: Monitoring for Side Effects

CAR-T therapy can trigger powerful immune responses. Doctors closely monitor patients for potential side effects, including:

Cytokine Release Syndrome (CRS): A strong immune reaction causing fever, low blood pressure, and inflammation.
Neurological Toxicity: Symptoms like confusion, difficulty speaking, or seizures.

Most side effects occur within the first few weeks after infusion and require careful management by the medical team.

Step 7: Recovery and Long-Term Monitoring

Patients need regular follow-ups to assess their response to treatment. In many cases, remission is achieved, but ongoing monitoring is essential to detect any signs of recurrence or long-term side effects.

Why CAR-T Therapy is a Game-Changer

For patients with relapsed or refractory blood cancers, CAR-T therapy has demonstrated remarkable success, with many achieving long-term remission. The treatment is a personalized and targeted approach, reducing harm to healthy cells compared to traditional chemotherapy and radiation.

Looking Ahead

While currently approved for certain types of leukemia and lymphoma, research is expanding CAR-T therapy's potential to solid tumors and other diseases. As advancements continue, accessibility and affordability remain key challenges, but the future of CAR-T therapy looks promising.

Frequently Asked Questions

In most cases, CAR-T therapy is a one-time infusion, but patients require close follow-up care to monitor response, manage side effects, and check for any recurrence of cancer.

CAR-T therapy has shown high success rates in certain blood cancers, with many patients achieving remission, especially in difficult-to-treat cases.

Common side effects include fever, low blood pressure, weakness, and neurological symptoms like confusion or difficulty speaking, especially in the first few weeks after treatment.

CAR-T therapy is mainly used for certain blood cancers such as leukemia, lymphoma, and some cases of multiple myeloma, especially when other treatments have not worked.